Header Logo

Connection

Anne-Marie Malfait to ADAM Proteins

This is a "connection" page, showing publications Anne-Marie Malfait has written about ADAM Proteins.
Connection Strength

2.957
  1. The "elusive DMOAD": Aggrecanase inhibition from laboratory to clinic. Clin Exp Rheumatol. 2019 Sep-Oct; 37 Suppl 120(5):130-134.
    View in: PubMed
    Score: 0.665
  2. Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis. Osteoarthritis Cartilage. 2016 Feb; 24(2):299-306.
    View in: PubMed
    Score: 0.502
  3. Reduced incidence and severity of experimental autoimmune arthritis in mice expressing catalytically inactive A disintegrin and metalloproteinase 8 (ADAM8). Clin Exp Immunol. 2009 Nov; 158(2):246-56.
    View in: PubMed
    Score: 0.328
  4. A review of the ADAMTS family, pharmaceutical targets of the future. Curr Pharm Des. 2009; 15(20):2359-74.
    View in: PubMed
    Score: 0.315
  5. ADAMTS-4 (aggrecanase-1): N-terminal activation mechanisms. Arch Biochem Biophys. 2005 Dec 01; 444(1):34-44.
    View in: PubMed
    Score: 0.253
  6. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage. 2015 Aug; 23(8):1254-66.
    View in: PubMed
    Score: 0.121
  7. Structure analysis reveals the flexibility of the ADAMTS-5 active site. Protein Sci. 2011 Apr; 20(4):735-44.
    View in: PubMed
    Score: 0.092
  8. Knockout of ADAMTS5 does not eliminate cartilage aggrecanase activity but abrogates joint fibrosis and promotes cartilage aggrecan deposition in murine osteoarthritis models. J Orthop Res. 2011 Apr; 29(4):516-22.
    View in: PubMed
    Score: 0.089
  9. ADAM-8 isolated from human osteoarthritic chondrocytes cleaves fibronectin at Ala(271). Arthritis Rheum. 2009 Sep; 60(9):2704-13.
    View in: PubMed
    Score: 0.082
  10. Proprotein convertase activation of aggrecanases in cartilage in situ. Arch Biochem Biophys. 2008 Oct 01; 478(1):43-51.
    View in: PubMed
    Score: 0.076
  11. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J Biol Chem. 2008 Jan 18; 283(3):1501-1507.
    View in: PubMed
    Score: 0.073
  12. Substrate-dependent inhibition kinetics of an active site-directed inhibitor of ADAMTS-4 (Aggrecanase 1). Biochemistry. 2007 May 29; 46(21):6393-401.
    View in: PubMed
    Score: 0.070
  13. Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate. J Biol Chem. 2007 Apr 13; 282(15):11101-9.
    View in: PubMed
    Score: 0.069
  14. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum. 2007 Feb; 56(2):575-85.
    View in: PubMed
    Score: 0.069
  15. Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. J Biol Chem. 2004 Apr 23; 279(17):17554-61.
    View in: PubMed
    Score: 0.056
  16. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem. 2002 Jun 21; 277(25):22201-8.
    View in: PubMed
    Score: 0.049
  17. Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors. J Biol Chem. 2009 Sep 04; 284(36):24185-91.
    View in: PubMed
    Score: 0.020
  18. Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (Aggrecanase-1) in the trans-Golgi network. J Biol Chem. 2004 Apr 09; 279(15):15434-40.
    View in: PubMed
    Score: 0.014
  19. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage. 2001 Aug; 9(6):539-52.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.